Cullinan Therapeutics (CGEM) Stock Overview
A clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CGEM Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cullinan Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.85 |
| 52 Week High | US$16.74 |
| 52 Week Low | US$5.68 |
| Beta | -0.16 |
| 1 Month Change | -17.10% |
| 3 Month Change | 26.73% |
| 1 Year Change | 60.22% |
| 3 Year Change | 25.61% |
| 5 Year Change | -68.85% |
| Change since IPO | -57.04% |
Recent News & Updates
Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist
Feb 23Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth?
Jan 23
Recent updates
Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist
Feb 23Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth?
Jan 23Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation
Oct 10Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation
Jun 21Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data
Apr 08Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans
Feb 27Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Jan 08Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans
Nov 20Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease
Aug 30Checking Into Cullinan Therapeutics
Jun 09Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth
Apr 23Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Sep 14Cullinan Oncology grants stock options for 125.7K shares
Sep 02Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Jun 24Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 05Shareholder Returns
| CGEM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | -0.7% | -1.9% |
| 1Y | 60.2% | 21.5% | 14.7% |
Return vs Industry: CGEM exceeded the US Biotechs industry which returned 21.6% over the past year.
Return vs Market: CGEM exceeded the US Market which returned 14.7% over the past year.
Price Volatility
| CGEM volatility | |
|---|---|
| CGEM Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CGEM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CGEM's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 109 | Nadim Ahmed | cullinantherapeutics.com |
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.
Cullinan Therapeutics, Inc. Fundamentals Summary
| CGEM fundamental statistics | |
|---|---|
| Market cap | US$777.76m |
| Earnings (TTM) | -US$219.88m |
| Revenue (TTM) | n/a |
Is CGEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$219.88m |
| Earnings | -US$219.88m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CGEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/29 03:43 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cullinan Therapeutics, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Samantha Lynn Semenkow | Citigroup Inc |
| Joshua Schimmer | Evercore ISI |